KetAImine™
搜索文档
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Newsfile· 2025-10-17 20:26
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA SaleOctober 17, 2025 8:26 AM EDT | Source: PharmaTher Holdings Ltd.Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamin ...
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Newsfile· 2025-10-15 20:00
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA FilingsExpanding ketamine indications, fortifying IP, enabling earlier partnerships, and accelerating FDA pathways - underpinned by PharmaTher's Digital Health AI division, leveraging the Company's FDA-approved ketamine ANDA CMC and KetaVault(TM) data advantage.October 15, 2025 8:00 AM EDT | Source: PharmaTher Holdings Ltd.Toronto, Ontario--(Newsf ...
